CAR-T cell therapy in Multiple Myeloma: current status and future challenges
D Swan, D Madduri, J Hocking - Blood Cancer Journal, 2024 - nature.com
The treatment of multiple myeloma has changed dramatically in recent years, with huge
strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B …
strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B …
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape of
relapsed/refractory multiple myeloma. The current Food and Drug Administration approved …
relapsed/refractory multiple myeloma. The current Food and Drug Administration approved …